


PHARMACEUTICAL 2023

RenovoRx Inc. Rank 282 of 446







PHARMACEUTICAL 2023

RenovoRx Inc. Rank 282 of 446

The relative strengths and weaknesses of RenovoRx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RenovoRx Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of RenovoRx Inc. is the variable Net Income, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 26% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,265
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	534
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	17
Other Expenses	0
Other Liabilities	568
Other Net Income	61
Other Revenues	0
Property and Equipment	0
Research and Development	4,301
Selling, General and Administrative Expense	5,649

Output Variable	Value in 1000 USD
Assets	7,265
Liabilities	1,102
Expenses	9,950
Revenues	0
Stockholders Equity	6,163
Net Income	-9,889
Comprehensive Net Income	-9,880
Economic Capital Ratio	17%

